

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

NCT05708534

Status RECRUITING
Sponsor University Hospital, Rouen
Enrollment 28 participants

Key Eligibility Criteria

Inclusion (7)

- Renal transplant follow-up at Rouen University Hospital
- Clinico-biological intolerance to anticalcineurins defined by GFR \leq 25 mL/min and/or water and sodium overload justifying the prescription of loop diuretics and/or post-transplant diabetes and/or resistant hypertension (requiring at least 3 treatments antihypertensives including a thiazide diuretic to reach an objective d 140/90 mmHg).
- Having performed a graft biopsy \leq 3 months old finding lesions of fibrous endarteritis e 2 or arteriolar hyalinosis e 2
- Having undergone collegial validation for the initiation of treatment with belatacept combined with 3-month anti-CMV prophylaxis with oral Valganciclovir.
- Absence of contraindication to belatacept
- ... and 2 more (see full listing online)

Exclusion (4)

- Patient with symptomatic infection
- Pregnant or parturient or breast-feeding woman or lack of proven effective contraception
- Person deprived of liberty by an administrative or judicial decision or person placed under legal safeguard / sub-tutorship or curatorship
- Patient participating in another therapeutic trial or having participated in another trial within 1 month

Locations (1 total)

University Rouen Hospital, Rouen, France